Loading company
Soligenix, Inc.
SNGX · Nasdaq · ·
Next earnings: November 6, 2026
$0.36-6.3%Sep 29 close
- 1M
- -4.5%
- 6M
- -67.6%
- 1Y
- -69.0%
- 5Y
- -99.9%
SNGX · Nasdaq · ·
Next earnings: November 6, 2026
$0.36-6.3%Sep 29 close
Soligenix, Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toDec 31, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $244.8K | -100.00% |
| Profit | -$2M | -$2.7M | +26.45% |
| Profit per share | -$0.12 | -$0.82 | +85.37% |
| Free Cash Flow | -$2.7M | -$2.5M | -8.52% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201). Our Vaccines/BioDefense business segment includes active development programs for RiVax ™ , our ricin toxin vaccine candidate, OrbeShield ® , our GI acute radiation syndrome therapeutic candidate and SGX943, our melioidosis therapeutic candidate. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax ® . Currently, this business segment is supported with up to $58 million in government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Soligenix, Inc.’s Item 2.02 8-K filed August 12, 2016; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Soligenix, Inc. has no earnings call transcript available.